Onconetix (ONCO) Revenue — Quarter Ended Mar 31, 2025
Revenue declined sharply in the current quarter. The decrease was steep compared with both the prior quarter and the same quarter a year earlier.
Key takeaway
Quarter ended Mar 31, 2025 · FY2025 Q1
Revenue declined sharply in the current quarter. The decrease was steep compared with both the prior quarter and the same quarter a year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$101.6K
Revenue reported for this quarter.
Quarter-over-quarter
-85.7%
Change from the immediately preceding quarter.
Year-over-year
-85.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$1.9M
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2024 | $704.8K | n/a |
| Sep 30, 2024 | $406.9K | n/a |
| Dec 31, 2024 | $712K | n/a |
| Mar 31, 2025 | $101.6K | -85.5% |
Revenue performance
Reported revenue fell substantially from the immediately preceding quarter. The year-over-year comparison also showed a significant drop.
Quarterly comparison
Revenue was lower than both the prior quarter and the same quarter one year ago. The sequential and year-ago declines were of similar magnitude.
What to watch
The company's cash position and going-concern uncertainty are noted in the filing context.